Lapatinib ditosylate
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 100946

CAS#: 388082-77-7 (ditosylate)

Description: Lapatinib is a synthetic, orally-active quinazoline with potential antineoplastic activity. Lapatinib reversibly blocks phosphorylation of the epidermal growth factor receptor (EGFR), ErbB2, and the Erk-1 and-2 and AKT kinases; it also inhibits cyclin D protein levels in human tumor cell lines and xenografts. EGFR and ErbB2 have been implicated in the growth of various tumor types. Check for active clinical trials or closed clinical trials using this agent.


Chemical Structure

img
Lapatinib ditosylate
CAS# 388082-77-7 (ditosylate)

Theoretical Analysis

MedKoo Cat#: 100946
Name: Lapatinib ditosylate
CAS#: 388082-77-7 (ditosylate)
Chemical Formula: C43H42ClFN4O10S3
Exact Mass:
Molecular Weight: 925.46
Elemental Analysis: C, 55.81; H, 4.57; Cl, 3.83; F, 2.05; N, 6.05; O, 17.29; S, 10.39

Size Price Shipping out time Quantity
1g USD 150 Same day
2g USD 250 Same day
5g USD 450 Same day
10g USD 650 Same day
20g USD 950 Same day
50g USD 1450 Same day
100g USD 2650 Same day
200g USD 3850 Same day
500g USD 5950 Same day
Inquire bulk and customized quantity

Pricing updated 2021-02-28. Prices are subject to change without notice.

Lapatinib ditosylate, purity > 98%, is in stock. The same day shipping out after order is received.

Related CAS #: 388082-77-7 (ditosylate)   231277-92-2 (free base)    

Synonym: GSK572016; GSK-572016; GSK 572016; GW2016; GW-2016; GW 2016; Lapatinib; Lapatinib ditosylate; Brand name: Tykerb. CAT#100490B.

IUPAC/Chemical Name: N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)furan-2-yl)quinazolin-4-amine ditosylate

InChi Key: UWYXLGUQQFPJRI-UHFFFAOYSA-N

InChi Code: InChI=1S/C29H26ClFN4O4S.2C7H8O3S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19;2*1-6-2-4-7(5-3-6)11(8,9)10/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35);2*2-5H,1H3,(H,8,9,10)

SMILES Code: O=S(CCNCC1=CC=C(C2=CC3=C(NC4=CC=C(OCC5=CC=CC(F)=C5)C(Cl)=C4)N=CN=C3C=C2)O1)(C)=O.OS(=O)(C6=CC=C(C)C=C6)=O.OS(=O)(C7=CC=C(C)C=C7)=O

Appearance:
Yellow solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 925.46 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Bowen JM. Development of the rat model of lapatinib-induced diarrhoea. Scientifica (Cairo). 2014;2014:194185. doi: 10.1155/2014/194185. Epub 2014 Jul 7. Review. PubMed PMID: 25126444; PubMed Central PMCID: PMC4121095.

2: Wang H. Lapatinib for the treatment of breast cancer in the People's Republic of China. Onco Targets Ther. 2014 Jul 31;7:1367-73. doi: 10.2147/OTT.S60586. eCollection 2014. Review. PubMed PMID: 25114575; PubMed Central PMCID: PMC4125370.

3: Abdel-Rahman O, Fouad M. Does the use of lapatinib increase the risk of fatigue and hepatic toxicities in patients with solid tumors? A critical literature review and meta-analysis. Expert Opin Drug Saf. 2014 Aug;13(8):999-1008. doi: 10.1517/14740338.2014.921679. Epub 2014 Jun 14. Review. PubMed PMID: 24930544.

4: Nolting M, Schneider-Merck T, Trepel M. Lapatinib. Recent Results Cancer Res. 2014;201:125-43. doi: 10.1007/978-3-642-54490-3_7. Review. PubMed PMID: 24756789.

5: Gandhi MD, Agulnik M. Targeted treatment of head and neck squamous-cell carcinoma: potential of lapatinib. Onco Targets Ther. 2014 Feb 13;7:245-51. doi: 10.2147/OTT.S46933. eCollection 2014. Review. PubMed PMID: 24611017; PubMed Central PMCID: PMC3928467.

6: Bianchi GV, Duca M, Sica L, Mariani G. Metastatic breast cancer treated with lapatinib with a prolonged benefit: a case report and a review of therapeutic options available. Tumori. 2013 Nov-Dec;99(6):269e-72e. doi: 10.1700/1390.15466. Review. PubMed PMID: 24503801.

7: Botrel TE, Paladini L, Clark OA. Lapatinib plus chemotherapy or endocrine therapy (CET) versus CET alone in the treatment of HER-2-overexpressing locally advanced or metastatic breast cancer: systematic review and meta-analysis. Core Evid. 2013;8:69-78. doi: 10.2147/CE.S50474. Epub 2013 Sep 30. Review. PubMed PMID: 24115917; PubMed Central PMCID: PMC3793631.

8: Larsen PB, Kümler I, Nielsen DL. A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer. Cancer Treat Rev. 2013 Nov;39(7):720-7. doi: 10.1016/j.ctrv.2013.01.006. Epub 2013 Mar 5. Review. PubMed PMID: 23481218.

9: Gross-Goupil M, Bernhard JC, Ravaud A. Lapatinib and renal cell carcinoma. Expert Opin Investig Drugs. 2012 Nov;21(11):1727-32. doi: 10.1517/13543784.2012.713935. Epub 2012 Aug 9. Review. PubMed PMID: 22876762.

10: Riemsma R, Forbes CA, Amonkar MM, Lykopoulos K, Diaz JR, Kleijnen J, Rea DW. Systematic review of lapatinib in combination with letrozole compared with other first-line treatments for hormone receptor positive(HR+) and HER2+ advanced or metastatic breast cancer(MBC). Curr Med Res Opin. 2012 Aug;28(8):1263-79. doi: 10.1185/03007995.2012.707643. Epub 2012 Jul 16. Review. PubMed PMID: 22738819.

11: Opdam FL, Guchelaar HJ, Beijnen JH, Schellens JH. Lapatinib for advanced or metastatic breast cancer. Oncologist. 2012;17(4):536-42. doi: 10.1634/theoncologist.2011-0461. Epub 2012 Apr 3. Review. PubMed PMID: 22477724; PubMed Central PMCID: PMC3336826.

12: Hurvitz SA, Kakkar R. Role of lapatinib alone or in combination in the treatment of HER2-positive breast cancer. Breast Cancer (Dove Med Press). 2012 Apr 3;4:35-51. doi: 10.2147/BCTT.S29996. Review. PubMed PMID: 24367193; PubMed Central PMCID: PMC3846547.

13: Fleeman N, Bagust A, Boland A, Dickson R, Dundar Y, Moonan M, Oyee J, Blundell M, Davis H, Armstrong A, Thorp N. Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis. Health Technol Assess. 2011;15(42):1-93, iii-iv. doi: 10.3310/hta15420. Review. PubMed PMID: 22152751.

14: Vrdoljak E, Boban M, Ban M. Lapatinib in the treatment of HER-2 overexpressing breast cancer. J BUON. 2011 Jul-Sep;16(3):393-9. Review. PubMed PMID: 22006739.

15: Kenny LM, Lam EW. Review: lapatinib in metastatic colorectal cancer-another strategy for disease control? Clin Adv Hematol Oncol. 2011 Jun;9(6):500-1. Review. PubMed PMID: 21841752.

16: Bouchalova K, Cizkova M, Cwiertka K, Trojanec R, Friedecky D, Hajduch M. Lapatinib in breast cancer - the predictive significance of HER1 (EGFR), HER2, PTEN and PIK3CA genes and lapatinib plasma level assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2010 Dec;154(4):281-8. Review. PubMed PMID: 21293538.

17: Merriam P, Sikov WM. Clinical utility of the combination of lapatinib and letrozole in the management of hormone receptor-positive and HER2-positive advanced breast cancer. Breast Cancer (Dove Med Press). 2011 Oct 26;3:139-50. doi: 10.2147/BCTT.S12150. Review. PubMed PMID: 24367183; PubMed Central PMCID: PMC3846896.

18: Giampaglia M, Chiuri VE, Tinelli A, De Laurentiis M, Silvestris N, Lorusso V. Lapatinib in breast cancer: clinical experiences and future perspectives. Cancer Treat Rev. 2010 Nov;36 Suppl 3:S72-9. doi: 10.1016/S0305-7372(10)70024-4. Review. PubMed PMID: 21129615.

19: MacFarlane RJ, Gelmon KA. Lapatinib for breast cancer: a review of the current literature. Expert Opin Drug Saf. 2011 Jan;10(1):109-21. doi: 10.1517/14740338.2011.533168. Epub 2010 Nov 20. Review. PubMed PMID: 21091041.

20: Arai H, Yamaki M, Nishimura Y. [Pharmacological profiles and clinical effects of lapatinib tosilate (Tykerb)]. Nihon Yakurigaku Zasshi. 2010 Sep;136(3):175-84. Review. Japanese. PubMed PMID: 20838021.  



Additional Information

Note: Previously we assigned 100490B for Lapatinib ditosylate.
New catalogue# for Lapatinib ditosylat is 100946, which was created on 2/10/2017.
CAT#100490B is the same product as CAT#100946.